At this year's Urologivecka in Sundsvall,
“These past four days have been filled with interesting meetings and discussions with urologists and nurses who have shown interest in our method. There is a clear consensus and a desire to explore and develop new focal treatment options for patients affected by recurrent prostate cancer," saysKristina Holst , Head of Clinical Affairs,SpectraCure .
"We can build strong relationships with leading urologists through active participation and visibility in these contexts. This enables us to establishSpectraCure as a trustworthy and reliable player in the industry and also to increase awareness of the ongoing clinical study," saysMasoud Khayyami , acting CEO,SpectraCure .
© Modular Finance, source